Janux Therapeutics vs Prelude Therapeutics
JANX and PRLD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JANX and PRLD compare
Janux Therapeutics is the larger company, worth 2.5 times as much as Prelude Therapeutics ($695M against $275M).
Prelude Therapeutics grew revenue faster over the last twelve months (220% versus 133% for Janux Therapeutics).
Prelude Therapeutics keeps more of each dollar of sales as profit, with a net margin of −270% compared with −429% at Janux Therapeutics.
Janux Therapeutics scores higher on the StockData Score (12 against 7 for Prelude Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JANX | PRLD |
|---|---|---|
| Size and price | ||
| Market cap | $695M | $275M |
| Share price | $11.37 | $3.45 |
| Change, 1 year | −60.1% | 135% |
| Change, 5 years | −36.4% | −76.1% |
| Beta (5Y) | 1.60 | 1.22 |
| Employees | 109 | 79 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 3 (better) | 1 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 29.8× | 12.3× (better) |
| P/B | 0.8× (better) | 2.1× |
| FCF yield | −7.8% (better) | −12.1% |
| Fair value | $16.54 | $2.06 |
| Margin of safety | 31.3% (better) | −67.1% |
| Growth | ||
| Revenue growth (TTM) | 133% | 220% (better) |
| Profitability | ||
| Operating margin | −599% | −301% (better) |
| Net margin | −429% | −270% (better) |
| FCF margin | −233% | −148% (better) |
| Return on equity | −10.6% (better) | −57.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 17.69 (better) | 4.07 |
| Altman Z-score | 5.85 (better) | −2.58 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 101% | 62.2% |
| Held by insiders | 21.3% | 40.5% |
| Insider net buying, 12 months | −$457K | $25.0M (better) |
| Short interest, % of float | 11.1% | 8.8% |
Go deeper
- JANX stock overview
- JANX income statement
- JANX valuation and score
- PRLD stock overview
- PRLD income statement
- PRLD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.